TASIGNA (nilotinib)
TherapyNovartis
TASIGNA (nilotinib) from Novartis is a BCR-ABL1–targeting therapy used in chronic myeloid leukemia.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and TASIGNA. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where TASIGNA is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Chronic Myeloid Leukemia (CML) Heme · Leukemia | t(9;21) Philadelphia chromosome
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TASIGNA.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TASIGNA for eligible patients.
Test
MRDx BCR-ABL Test
MolecularMD Corporation
Method
PCR
Specimen
Whole blood
1 approvalView test profile →